385 related articles for article (PubMed ID: 32559419)
1. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.
Mehta P; Porter JC; Manson JJ; Isaacs JD; Openshaw PJM; McInnes IB; Summers C; Chambers RC
Lancet Respir Med; 2020 Aug; 8(8):822-830. PubMed ID: 32559419
[TBL] [Abstract][Full Text] [Related]
2. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.
Bonaventura A; Vecchié A; Wang TS; Lee E; Cremer PC; Carey B; Rajendram P; Hudock KM; Korbee L; Van Tassell BW; Dagna L; Abbate A
Front Immunol; 2020; 11():1625. PubMed ID: 32719685
[TBL] [Abstract][Full Text] [Related]
3. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.
Lang FM; Lee KM; Teijaro JR; Becher B; Hamilton JA
Nat Rev Immunol; 2020 Aug; 20(8):507-514. PubMed ID: 32576980
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
6. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
[TBL] [Abstract][Full Text] [Related]
7. Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
Verrall GM
Front Immunol; 2020; 11():2167. PubMed ID: 33013911
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
9. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
10. COVID-19: In the Eye of the Cytokine Storm.
de la Rica R; Borges M; Gonzalez-Freire M
Front Immunol; 2020; 11():558898. PubMed ID: 33072097
[TBL] [Abstract][Full Text] [Related]
11. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
12. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
13. A rationale for targeting the P2X7 receptor in Coronavirus disease 19.
Di Virgilio F; Tang Y; Sarti AC; Rossato M
Br J Pharmacol; 2020 Nov; 177(21):4990-4994. PubMed ID: 32441783
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation in COVID-19.
Ingraham NE; Lotfi-Emran S; Thielen BK; Techar K; Morris RS; Holtan SG; Dudley RA; Tignanelli CJ
Lancet Respir Med; 2020 Jun; 8(6):544-546. PubMed ID: 32380023
[No Abstract] [Full Text] [Related]
15. Tackling the cytokine storm in COVID-19, challenges and hopes.
Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
17. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
[TBL] [Abstract][Full Text] [Related]
18. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
19. Therapeutic Potential of B-1a Cells in COVID-19.
Aziz M; Brenner M; Wang P
Shock; 2020 Nov; 54(5):586-594. PubMed ID: 32604223
[TBL] [Abstract][Full Text] [Related]
20. Macrophage responses associated with COVID-19: A pharmacological perspective.
Booz GW; Altara R; Eid AH; Wehbe Z; Fares S; Zaraket H; Habeichi NJ; Zouein FA
Eur J Pharmacol; 2020 Nov; 887():173547. PubMed ID: 32919938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]